Craig J. Justman, PhD

Craig Justman, PhD was raised in Fruita, CO.  He earned a AB in Biochemistry from Occidental College and a PhD in Chemistry & Chemical Biology from Harvard University, followed by postdoctoral work at Harvard Medical School.  His career in biotech has focused on developing disease-modifying therapies for neurodegenerative diseases, first at Link Medicine Corp (2005-2011), then at Lysosomal Therapeutics, Inc (2013-2022). At Lysosomal Therapeutics, he was on the team that developed an allosteric activator of glucocerebrosidase, which is now in Phase 2 for the treatment of GBA1-PD, a genetic subtype of Parkinson’s disease. He co-founded CeraLink Therapeutics in 2025, which is focused on developing therapeutics for Parkinson’s disease.